A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Proportion of patients at week 16 achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 and at least a 2-point reduction from their baseline value

The vIGA-AD scale ranges from 0 to 4, with higher score indicating more severe atopic dermatitis.

Time frame: Week 0 and Week 16

Proportion of patients at week 16 achieving a Eczema Area and Severity Index reduction of 75% relative to their baseline score (EASI-75)

The EASI scores range from 0 to 72, with higher score indicating more severe atopic dermatitis.

Time frame: Week 0 and Week 16

Proportion of patients at week 16 achieving a Eczema Area and Severity Index reduction of 90% relative to their baseline score (EASI-90)

The EASI scores range from 0 to 72, with higher score indicating more severe atopic dermatitis.

Time frame: Week 0 and Week 16

Proportion of patients at week 16 achieving a Eczema Area and Severity Index reduction of 50% relative to their baseline score (EASI-50)

The EASI scores range from 0 to 72, with higher score indicating more severe atopic dermatitis.

Time frame: Week 0 and Week 16

Proportion of patients at week 16 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of patients with a 4-point or greater Itch NRS at baseline

The itch NRS goes from 0 to 10, with higher score indicating more severe itch.

Time frame: Week 0 and Week 16

Proportion of patients at week 16 achieving a SCORing Atopic Dermatitis Index (SCORAD) reduction of 75% from their baseline value

The SCORAD scores range from 0 to 103, with a higher score indicating more severe atopic dermatitis.

Time frame: Week 0 and Week 16

Proportion of patients at week 16 achieving a SCORAD reduction of 50% from their baseline value

The SCORAD scores range from 0 to 103, with a higher score indicating more severe atopic dermatitis.

Time frame: Week 0 and Week 16

Mean change from baseline over the period between week 0 and week 104 in Eczema Area and Severity Index (EASI)

The EASI scores range from 0 to 72, with higher score indicating more severe atopic dermatitis.

Time frame: From Week 0 through Week 104

Mean percent change from baseline over the period between week 0 and week 104 in Eczema Area and Severity Index (EASI)

The EASI scores range from 0 to 72, with higher score indicating more severe atopic dermatitis.

Time frame: From Week 0 through Week 104

Mean change from baseline over the period between week 0 and week 104 in SCORAD

The SCORAD scores range from 0 to 103, with a higher score indicating more severe atopic dermatitis.

Time frame: From Week 0 through Week 104

Mean percent change from baseline over the period between week 0 and week 104 in SCORAD

The SCORAD scores range from 0 to 103, with a higher score indicating more severe atopic dermatitis.

Time frame: From Week 0 through Week 104

Mean change from baseline over the period between week 0 and week 104 in body surface area (BSA) involvement

Time frame: From Week 0 through Week 104

Mean percent change from baseline over the period between week 0 and week 104 in body surface area (BSA) involvement

Time frame: From Week 0 through Week 104

Rezpegaldesleukin plasma concentration assessed throughout the study

Time frame: Through end of study (week 104)

Incidence of Serious Adverse Events (SAEs)

Time frame: Through end of study (week 104)

Incidence of Treatment Emergent Adverse Events (TEAEs)

Time frame: Through end of study (week 104)